We evaluated the utility of plasma polymerase chain reaction (PCR) for surveillance of human herpes virus 6 (HHV-6) infection among pediatric bone marrow transplant (BMT) recipients. We used a prospective, non-interventional design involving a study group and controls. BMT recipients and healthy controls were evaluated. BMT subjects had HHV-6 PCR done biweekly for 12 weeks post transplantation, while a single PCR test was done on controls. For the PCR assay, EDTA blood was collected and DNA extracted from whole blood and cell-free plasma using standard procedures. The PCR was first performed on DNA from whole blood and if a positive result was obtained, the test was repeated on the DNA from the plasma. Thirty BMT recipients (13 autologous and 17 allogeneic) were enrolled, on whom a total of 156 PCR tests were performed, while six tests were done on six healthy controls. The median age of BMT subjects was 6.2 years (range 0.5-17.5 years). The median age of the control subjects was 6.6 years (range 2-10 years). Among asymptomatic BMT patients who had PCR surveillance, the positivity rate was 3.3% (1/30) on whole blood and 0% (0/30) on plasma. None of the six healthy subjects had a positive PCR test on whole blood. During the period of the surveillance study, 14 patients had diagnostic evaluations for HHV-6 disease because of clinical symptoms. Two of these patients were diagnosed with disease associated with HHV-6 (graft failure and encephalitis) and had positive PCR tests on whole blood and plasma and whole blood and cerebrospinal fluid, respectively. We conclude that despite the fact that HHV-6 seropositivity rates are high among children, the frequency of HHV-6 plasma PCR positivity is low in pediatric BMT subjects who are asymptomatic for HHV-6 disease. Given that a positive test on plasma is consistent with active infection, this increases the utility of the PCR test as a
Human herpes virus-6 (HHV6) is the causative agent of exanthem subitum (roseola). 1, 2 It was first isolated in 1986 from immunocompromised adults, 3 and is increasingly being recognized as one of the infectious disease challenges facing bone marrow transplant (BMT) recipients. 4 This infection is normally acquired at an early age with seroprevalence data indicating that by the age of 2 years greater than 90% of children have already seroconverted. 4 Thus, the vast majority of individuals go into bone marrow transplantation with latent HHV-6 infection. This is similar to what would be expected when BMT recipients are seropositive for other herpes group viruses. In addition, transplant recipients who are seronegative for HHV-6 pretransplantation may become infected from donated organs and tissues. 5, 6 In this situation, the virus may be transmitted in donated peripheral blood lymphocytes.
Within the transplant population, BMT patients have been most extensively evaluated for HHV-6 disease. [7] [8] [9] [10] [11] [12] [13] In this population, HHV-6 has reportedly been associated with skin rashes, graft-versus-host disease, pneumonitis, sinusitis, febrile episodes, graft failure, encephalitis and in some cases with a fatal outcome. 4 While serological methods are available for determining the presence of HHV-6 infection in healthy individuals, 14 such methods have limited utility in immunocompromised patients. 12 Thus, finding the most suitable method of surveillance and diagnosis of HHV-6 disease post transplant is a challenge. This is related to the poor specificity of the tests used to diagnose disease (eg HHV-6 PCR on tissue) making it difficult to firmly establish HHV-6 as the cause of the clinical syndromes occurring in the post-transplant period. The use of PCR to detect HHV-6 DNA in blood cells or tissue has limited value in diagnosing active HHV-6 infection. 15 One testing modality that has been proposed involves the use of PCR for HHV-6 DNA on plasma samples. 14, 16 This is a sensitive and specific PCR test for detecting cell-free HHV-6 virions, which are regarded as being consistent with active HHV-6 replication, as opposed to latent infection. 16 This report describes the results of a pilot study that evaluated the role of HHV-6 PCR on plasma as an early indicator of increased HHV-6 replication and as a means of surveillance of HHV-6 disease among pediatric bone marrow transplant recipients. Besides documenting the background HHV-6 positivity as detected by the PCR test on plasma, we have described our experience with this testing modality as a diagnostic tool for HHV-6 disease positivity during the period of the above study.
Methods

Target population and eligibility criteria
This study involved pediatric bone marrow transplant recipients at the Hospital for Sick Children, Toronto. We included all eligible allogeneic and autologous BMT recipients. Eligible subjects were those less than 18 years of age. Informed consent was obtained for study subjects, as well as controls. Subjects were enrolled between October 1998 and April 1999.
Design features
This was a prospective, non-interventional study, involving a study group and controls. Control subjects were healthy children less than 18 years of age with no underlying chronic diseases. These subjects were selected from children having minor elective surgery. Informed consent was obtained from these controls.
Study procedure
Eligible subjects were enrolled consecutively until the required sample size was reached. A single blood sample was taken pre-transplantation to determine the HHV-6 serological status of study subjects. Control subjects had blood taken for HHV-6 serology and PCR. Samples for PCR were obtained on BMT recipients biweekly for 12 weeks post transplantation. Clinical and laboratory data were collected at the time of sampling on all BMT recipients.
Separate from the prospective surveillance above, we used HHV-6 PCR on blood and plasma to assist in diagnosing disease associated with HHV-6. In this way, patients with clinical syndromes that could be consistent with HHV-6 had PCR done on blood and plasma, in addition to PCR testing on biopsy samples or cerebrospinal fluid as indicated.
Laboratory procedures
Serology for HHV-6 was done using an enzyme-linked immunosorbent assay (Advanced Biotechnologies, Rivers Park, MD, USA). For the PCR analyses on blood or plasma, 3 ml of anticoagulated EDTA blood was taken from each child. On the arrival of the sample in the laboratory, two aliquots were established. First, a whole blood aliquot was frozen at −20°C; second, following removal of peripheral blood mononuclear cells by centrifugation, a plasma aliquot was also frozen at −20°C. DNA was subsequently extracted from 200 l of blood and 200 l of plasma aliquots, respectively, using the blood and tissue Qiagen extraction kit (Mississauga, Ontario, Canada) according to the manufacturer's recommendations. Although the primary objective was to evaluate the PCR on plasma, the test was first performed on a whole blood sample and if a positive result was obtained, the test was repeated on the plasma sample. Thus, in this report when reference is made to PCR testing on plasma, the understanding is that an initial screen is always done on whole blood.
Detection of HHV-6 by PCR was performed using a PCR methodology as previously described. 17 We used a pair of primers that amplify HHV-6, HHV-7 and varicella-zoster virus (VZV). The confirmation and species determination was provided by restriction enzyme digestion (we used BamHI (Life Technologies, Burlington, Ontario, Canada) and BstUI (New England Biolabs, Mississauga, Ontario, Canada)); the pattern of restriction fragments enabled us to distinguish between HHV-6 variant A and variant B. Based on serial dilutions of HHV-6 variant A DNA, the sensitivity of the PCR was estimated to be 1-10 genomic copies. 17 In addition to HHV-6 surveillance, all patients had concurrent surveillance testing for CMV using the pp65 antigenemia assay on a weekly basis. Ganciclovir prophylaxis was employed for CMV prevention using a universal prophylaxis strategy. In keeping with our usual clinical practice, all clinical syndromes consistent with infection were extensively evaluated to rule out the presence of opportunistic infections, including CMV, HHV-6 and other viral disease. Testing modalities included histopathology, viral culture and PCR as appropriate.
Statistical analyses
Data management and analyses were facilitated by Epi Info Software (Epi Info, version 6; Centers for Disease Control and Prevention, Atlanta, Georgia, 1994). Descriptive summary statistics were performed and wherever appropriate the statistical plan was for proportions to be compared using chi-square or Fisher's exact tests.
Results
Thirty pediatric BMT recipients were assessed with serial HHV-6 PCR testing. Table 1 shows their characteristics. Among the allograft recipients, nine had matched unrelated donors (6/6 match, n = 8; 5/6 match, n = 1). Eight allogeneic recipients received marrow from related donors (6/6 match, n = 6, 5/6 match, n = 2). Among allogeneic subjects, ganciclovir or acyclovir prophylaxis was administered in 94.1%. While ganciclovir was not used in the patients receiving autologous transplants, acyclovir was administered to 30.8% of this group. Twenty-six of 30 BMT recipients (86.7%) were documented to be seropositive for HHV-6 pre-transplantation by ELISA. The control group con- sisted of six healthy children with a median age of 6.7 years (range 2-10 years). Among the 17 patients who had allogeneic grafts, the stages of GVHD were as follows: grade 0-I, n = 8; grade II, n = 6; grade III-IV, n = 3. With respect to the various immunosuppressive medications used, the allogeneic subjects received the following agents: cyclosporine 7.7% (1/13), cyclosporine and corticosteroids 76.9% (10/13) and cyclosporine, corticosteroids and antithymocyte globulin 15.4% (2/13). Of the four allogeneic subjects who did not have GVHD, two received cyclosporine, while two received both cyclosporine and corticosteroids.
Surveillance for HHV-6
In the surveillance study, 156 PCR tests were performed prospectively on whole blood from 30 BMT recipients (average of 5.2 tests per patient). In addition, the six control subjects each had one test performed. There was one positive PCR for HHV-6 variant B (HHV6-B) on whole blood (1/30), with no positive tests on plasma (0/30). Blood samples from the healthy control subjects were negative for HHV-6 DNA. HHV-7 was detected in the whole blood of one patient, while VZV was detected in the whole blood of two patients. Of these two latter patients, one developed herpes zoster 2 weeks later, while the other had presumptive clinical evidence of disseminated varicella infection in the absence of skin lesions. The low rate of HHV-6 PCR positivity precluded a meaningful comparison of the proportion of positive tests among allogeneic vs autologous BMT recipients.
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Evaluation of clinical syndromes
Patients with clinical syndromes consistent with herpes viral diseases were extensively evaluated according to our usual practice. In addition, these patients had HHV-6 PCR done on plasma to assist in the diagnostic evaluation. Altogether 14 patients had diagnostic evaluation with HHV-6 PCR during the period of the surveillance study. These subjects were separate from the 30 subjects in the surveillance study and therefore HHV-6 surveillance testing as previously described was not performed. Two of the above 14 patients were diagnosed with HHV-6 disease and subsequently died. Extensive virologic evaluations suggested than in the absence of other explanations for these patients' illnesses, HHV-6 was the most likely cause. In this regard, one of these patients had graft failure attributed to HHV-6, while the other had graft-versus-host disease, bone marrow suppression, encephalitis and a generalized vesicular rash. In both patients, HHV-6B was detected by PCR on blood, while the patient with graft failure only also had a positive test on plasma. The presence of HHV-6 B was also demonstrated by PCR in the cerebrospinal fluid in the presence of an encephalitic illness in the other patient. In this latter patient, HHV-6B was detected by PCR in biopsy samples from the colon as part of the evaluation of possible colitis. HHV-6B DNA was detected in vesicular fluid aspirate from a skin lesion, while it was negative for VZV by electron microscopy and PCR. The presence of HHV-6 DNA in this sample was presumed to be due to trace amounts of blood in the sample.
Discussion
This study indicates a low prevalence of HHV-6 PCR positivity on whole blood and plasma samples from pediatric BMT recipients. During the study period, the individuals who had evidence of HHV-6 disease had a poor outcome. The results suggest that in our setting a positive HHV-6 PCR on blood or plasma is an infrequent event and when it is documented, the clinical importance may be profound.
We evaluated both allogeneic and autologous BMT recipients in order to examine if the extent of matching and the level of immune suppression would affect the rate of HHV-6 PCR positivity. The patients with positive HHV-6 PCR on blood and/or plasma received allogeneic transplants. Prophylaxis with ganciclovir and acyclovir was used in study patients. It is unclear if this may have affected the rate of detection of a positive PCR on blood or plasma. Ganciclovir is active against some strains of HHV-6, while acyclovir is not. Our study was not sufficiently powered to evaluate the effect of antiviral prophylaxis. However, both patients who developed clinical syndromes consistent with HHV-6 disease, were on acyclovir prophylaxis at the time of the positive HHV-6 PCR.
Studies that have targeted analysis of HHV-6 in peripheral blood mononuclear cells that have been purified by selecting the buffy coat have documented higher rates of detection. [8] [9] 11, 12, 18 However, it has been documented that benign periodic HHV-6 reactivation occurs throughout the post-transplant period. In a study by Cone et al, 12 HHV-6 DNA was detected in PBMC by PCR in all 20 transplant patients and nine of 19 healthy control studies. The relatively high rate of detection of HHV-6 in PBMCs from control subjects limits the utility of this approach for BMT recipients, unless a quantitative approach is used. 12 In addition, this approach is unsatisfactory unless good enough engraftment has occurred to provide adequate cell numbers for analysis.
We did not evaluate HHV-6 antibody titers post transplantation. This is in keeping with the finding that these titers generally do not reflect PBMC HHV-6 activity following transplantation. 12 Such antibody levels may fluctuate in the absence of increased viral activity. In addition, significantly immunocompromised patients mount poor antibody responses to their viruses. Patients who experience other herpes group infections may have increases in HHV-6 antibody titers. 19 In general, antibody titers have not proved helpful in evaluating other herpes group viral diseases post transplantation (eg cytomegalovirus (CMV), Epstein-Barr virus).
In our study, we included patients regardless of CMV serostatus pretransplantation. Thus, the low plasma HHV-6 PCR detection rate occurred in the setting of different donor and recipient CMV serostatus.
Co-infection with other herpes viruses has been documented among patients with pneumonitis due to HHV-6. 20 However, the precise role of HHV-6 in causing disease post transplantation remains the subject of debate. In this report, the two cases in whom clinical syndromes were attributed to HHV-6 provide evidence for a role of this virus in the clinical syndromes described. However, in these situations, it may be difficult to determine if the virus is playing a primary or a co-factor role in the pathogenesis of the observed clinical syndrome. In any event, in our setting the finding of a clinical syndrome consistent with HHV-6 in the presence of a positive HHV-6 PCR on plasma is taken as an indication for treatment of HHV-6 disease. In the presence of bone marrow failure, we have used foscarnet in preference to ganciclovir as the drug of first choice for treating HHV-6 disease. 4 One limitation of our study is that we did not compare HHV-6 detection rates as a result of targeting PBMCs concentrated by buffy coat vs aliquots of blood and plasma. It is likely that PCR testing of concentrated PBMCs will yield a greater rate of positivity, related in part to the fact that a larger number of PBMCs are used when they are separated by buffy coat, compared to the volume of blood used in our study. Given the finding by Cone et al, 12 it is likely that the HHV-6 PCR on plasma is a more specific indicator of clinically significant increased HHV-6 replication. This issue notwithstanding, one question is whether the HHV-6 PCR test starting from 200 l of blood or plasma was sensitive enough to detect low levels of HHV-6 replication. In this context, in addition to the measured sensitivity on serially diluted DNA samples, 17 the high sensitivity of our PCR detection system is supported by an incidental finding during the period of the study when we detected varicella zoster DNA in the blood of a patient who developed cutaneous herpes zoster 2 weeks later. Subclinical VZV viremia prior to clinical signs of herpes zoster has been previously reported. 21 The high sensitivity of the PCR assay is supported by the fact that another patient also had a positive PCR for VZV in whole blood in the absence of skin lesions. Four weeks after bone marrow transplantation, this patient with presumed VZV disseminated disease without skin manifestation presented with a septic shock/cytokine storm-like picture accompanied by upper gastrointestinal bleeding. An infectious disease evaluation was entirely negative, except for VZV present in both whole blood and plasma, as well as from a gastric biopsy. Unfortunately, the clinical status of the patient precluded other biopsies (including liver biopsy). Visceral varicella zoster infection without skin involvement after BMT has been previously described. 22 The results of our study support the selective use of HHV-6 PCR on whole blood and plasma in evaluating bone marrow transplant recipients for disease related to HHV-6. The PCR on whole blood and plasma may be useful in evaluating clinical scenarios in which HHV-6 is considered a likely etiologic agent. The routine sequential testing for HHV-6 is likely to be less useful in our setting. The results highlight the importance of evaluating PCR testing modalities in the setting in which the results will be applied, rather than extrapolating from data generated in other settings. Additional prospective studies are needed to compare different testing modalities as the first step in firmly establishing the full spectrum of clinical syndromes that may be caused by this virus in pediatric BMT recipients.
